Provided by Tiger Trade Technology Pte. Ltd.

Praxis Precision Medicines, Inc.

327.37
+10.123.19%
Volume:224.87K
Turnover:72.29M
Market Cap:8.97B
PE:-25.33
High:330.00
Open:315.22
Low:314.35
Close:317.25
52wk High:335.75
52wk Low:26.70
Shares:27.41M
Float Shares:22.92M
Volume Ratio:0.74
T/O Rate:0.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.9227
EPS(LYR):-10.2095
ROE:-75.20%
ROA:-45.09%
PB:26.12
PE(LYR):-32.07

Loading ...

Earning Preview: Praxis Precision Medicines, Inc. Q4 revenue is expected to decrease by 88.06%, and institutional views are bullish

Earnings Agent
·
Feb 12

Praxis Precision Medicines Updates Non-Employee Director Compensation Policy

Reuters
·
Feb 11

Praxis Precision Med Is Maintained at Buy by Guggenheim

Dow Jones
·
Feb 10

Praxis Precision Medicines Inc. published an update to their financial calendar

Reuters
·
Feb 10

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

GlobeNewswire
·
Feb 10

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.
·
Feb 09

Praxis Precision Medicines Grants Restricted Stock Units to New Employees Under 2024 Inducement Plan

Reuters
·
Feb 05

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 05

Praxis Precision Med Is Maintained at Buy by Needham

Dow Jones
·
Feb 04

Needham Upside Case: Strong Ulixacaltamide Outlook and 2026 Catalyst Stack Drive Praxis Buy Thesis

TIPRANKS
·
Feb 04

Praxis Precision Med Initiated at Equal-Weight by Wells Fargo

Dow Jones
·
Feb 02

Wells Fargo Initiates Coverage on Praxis Precision Medicines With Equal Weight Rating, $282 Price Target

MT Newswires Live
·
Feb 02

Praxis Precision Med Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 31

Praxis Precision Medicines Inc : TD Cowen Raises Target Price to $554 From $353

THOMSON REUTERS
·
Jan 29

TD Cowen Remains a Buy on Praxis Precision Medicines (PRAX)

TIPRANKS
·
Jan 29

Praxis Precision Med Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Jan 28

Praxis Precision Medicines Appoints Dr. Orrin Devinsky as Head of Clinical Strategy

Reuters
·
Jan 14

Praxis Precision Medicines Appoints Global Epilepsy Leader DR. Orrin Devinsky as Head of Clinical Strategy

THOMSON REUTERS
·
Jan 14

Praxis Precision Medicines Inc. Files Initial Statement of Beneficial Ownership for Director Jeffrey B. Kindler

Reuters
·
Jan 13

Praxis Precision price target raised to $95 from $83 at Wedbush

TIPRANKS
·
Jan 12